Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

inalimarev

A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:recombinant vaccinia-CEA-MUC1-TRICOM vaccine
recombinant vaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine
rVaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine
vaccinia-CEA-MUC-1-TRICOM vaccine
US brand name:PANVAC-V
Abbreviation:vCEA-MUC-1-TRI
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search